Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Srishti Gupta
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 30
- Beta
- 1.50
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 12.07
Financials
Revenue
$0.00-100.0%Net Income
$-18.87MEBITDA
$-20.26MFree Cash Flow
$-16.90MEPS (diluted)
$-0.16Shares Outstanding (diluted)
115.72M+98.9%Operating Expenses
$20.30MCash & Debt
$190.85MReturn of Capital
$0.00Revenue by Segment (annual)
$27.64MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-6.61M | $-0.16 |
| 2024 | $0.00 | $-162.26M | $-4.46 |
| 2023 | $4.49M | $-1.47B | $-17.62 |
| 2022 | $-10.70M | $-967.52M | $-30.38 |
| 2021 | $88.03M | $-2.33B | $-30.70 |
| 2020 | $1.54B | $470.92M | $8.07 |
| 2019 | $30.00M | $-1.45B | $-25.53 |
| 2018 | $53.78M | $-402.83M | $-6.92 |
| 2017 | $11.27M | $-298.24M | $-5.13 |
Valuation
NBPhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·28d ago·Neutral
…vaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director ROCKVILLE, Md., Sept. 08, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, today announced the appointment of Martin Dewhurst to its Board of Directors (the “Board”) as an independent director, and as a memb…
View source ↗ - Newsglobenewswire.com·40d ago·Neutral
NovaBridge Biosciences to Participate in September Investor Conferences ROCKVILLE, Md., Aug. 27, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, today announced that the Company's leadership will participate in the following investor conferences in September 2026: Conference details: Cant…
View source ↗ - Newsseekingalpha.com·46d ago·Positive
NovaBridge Biosciences (NBP) Q2 2026 Earnings Call Transcript NovaBridge Biosciences (NBP) Q2 2026 Earnings Call Transcript
View source ↗ - Newsglobenewswire.com·47d ago·Positive
…alf 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution ROCKVILLE, Md., Aug. 20, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, today reported financial results for the six months ended June 30, 2026, and provided a business update. During the first half of 20…
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
… 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026 ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, today announced that it will hold a webcast on Thursday, August 20, 2026 at 9:00 AM ET/9:00 PM China Standard Time to discuss recent…
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.08 per share
Typical surprise +58.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 20$-0.02 vs $-0.03beat
- Thu, Jul 30$-0.22 vs $-0.01miss
- Thu, Dec 18$-0.03 vs $-0.06beat
- Tue, Aug 26$-0.03 vs $-0.06beat
- Thu, May 15$-0.02 vs $-0.06beat
- Mon, Mar 31$-0.06 vs $-0.06beat
Estimates and results for NBP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NBP officers and directors.
- Bought
- $577k
- Sold
- $154k
1 trade
7 trades
- Dennis Phillip Andrewsold
- Cao Sean Wuxiongsold
- Xu Cong Clairesold
- Xu Cong Clairesold
- Dennis Phillip Andrewsold
- Xu Cong Clairesold
- Cao Sean Wuxiongsold
- Hagler Mark Arnoldbought
71 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NBP.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.